I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Chronic mucocutaneous candidiasis (CMC) is a persistent and recurrent infection mostly caused by the opportunistic pathogen *Candida albicans*. The most common lesions include whitish plaques associated to crusts and ulcers on the oral mucosa. This clinical entity starts during infancy for most of the patients. Defect associates with *Candida* recognition (e.g. CARD9 and Dectin 1), T helper 17 (Th17) differentiation (e.g. STA1 and STAT3 mutations), and cytokine 17 (IL-17) signaling (e. g anti-IL17 autoantibodies and TRAF3IP2 mutation) have been described.\[[@ref1][@ref2][@ref3]\] CMC is frequently associated with inherited or acquired T-cell deficiencies such as autoimmune polyendocrine syndrome type 1 (APS-1), autosomal-dominant hyper IgE syndrome, or HIV infection which leads to disruption of the effective mucosal response.\[[@ref4][@ref5][@ref6]\] Patients with APS-I have a loss of function in the AIRE gene which results in high titers of autoantibodies against Th17. Patients with hyper IgE syndrome have a loss of function by STAT 3 gene mutations, which results in a reduction of Th17 cell number and impaired cytokine production IL-17, as also occurs in STAT 1 mutation; STAT 1 gain-of-function mutations are associated with a variety of phenotypes including CMC, fungal infections other than candidiasis, bacterial and viral infections, mycobacterial infections, autoimmune disorders, and carcinomas and aneurysms.\[[@ref2][@ref7]\] STAT1 is identified in approximately 40% of patients with CMC.\[[@ref8]\]

For the treatment of chronic infections caused by *C. albicans*, azoles are considered the mainstay of therapy, in particular fluconazole because of high bioavailability after oral administration.\[[@ref9]\] Although treatment with azoles can be effective, long-term use of fluconazole has led to the emergence of *Candida* strains with decreased susceptibility.\[[@ref7]\] The present article describes retrospectively a case of a patient with CMC who presented with recurrent *C. albicans* infection since he was 6 months old. Susceptibility testing was performed for all the *C. albicans* isolates recovered during a 4-year period. Genotyping was carried out using the multilocus sequence typing (MLST) methodology to identify the population structure.

Case description: A 25-year-old male was admitted to the Hospital in February 2012 with history of recurrent fungal infections of the oral cavity and bacterial infections of the skin and respiratory tract. He was treated intermittently as an outpatient with fluconazole and nystatin for 20 years. On admission physical examination, white cotton-like plaques widely distributed in the oral cavity, hypertrophic mucosa, cheilitis \[[Figure 1a](#F1){ref-type="fig"}\], and signs of onychomycosis were observed. Fluconazole was switched to itraconazole, leading to resolution of the lesions within 2 months. However, he had a new relapse 3 months later. A palate biopsy was performed, and cultures were done because an infection by a different yeast was suspected. The susceptibility tests showed fluconazole-, itraconazole-, and voriconazole-resistant *C. albicans* isolates. Posaconazole was started without improvement; therefore, caspofungin was indicated for 14 days, but there was no recovery. The infectious diseases medical board decided to initiate amphotericin B deoxycholate (1 mg/kg/day) for 14 days upon treatment failure with echinocandins. Amphotericin B was continued as suppressive therapy for 2 months with slight improvement but no remission. Caspofungin alone and in combination with posaconazole and amphotericin B were given subsequently with partial improvement. In a different institution, genetic studies for CMC were made, revealing the STAT-1 mutation and confirming of immunocompromised related with diagnosis of CMC. Most antifungal therapies were empirical because at that time, the susceptibility profile of the isolates was not available. During a 4-year period, since his admission, samples from different lesions were cultured and the 16 recovered isolates were identified as *C. albicans* by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Retrospectively antifungal susceptibility testing was performed using the Clinical and Laboratory Standards Institute broth microdilution method (CLSI-BMD) \[[Figure 2b](#F2){ref-type="fig"}\].

![Patient\'s lesion and eBURST diagram. (a) Lesions of chronic mucocutaneous candidiasis patient: White cotton-like plaques widely distributed in the oral cavity, hypertrophic mucosa, and cheilitis. (b) The illustration shows the figure generated by eBURST 3.0 software, in which diploid sequence types are linked when they differ in the sequence of just one of the seven gene fragments used for MLST. The lengths of lines are not significant. The lines indicate differences between diploid sequence types that result from a loss of heterozygosity from the putative parent to the putative-derived isolate or from mutation, gene exchange, or another mechanism](JGID-12-16-g001){#F1}

![Characteristics of *Candida* spp. isolates. (a) Antifungal treatment over time. (b) Antifungal susceptibility results](JGID-12-16-g002){#F2}

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

A 4-year (2012--2016) retrospective study was conducted to recover yeast isolates in a CMC patient admitted to the Hospital.

Culture and identification {#sec2-1}
--------------------------

The samples were seeded on CHROMagar *Candida* plates (CHROMagar Candida, France) and Sabouraud dextrose agar (SDA, Merck, Germany). The cultures were incubated at 35°C for 36 h, and the identification of yeast was performed by MALDI-TOF MS. Protein extraction was performed with the formic acid/ethanol method, according to the Bruker Daltonics protocol. Briefly, two or three colonies were mixed with 300 μl of ultrapure water until homogenization and 600 μl of 100% ethanol was added (Sigma-Aldrich, St. Louis, MO). After centrifugation at 15,000 g for 2 min, the pellet was dried at 25°C and reconstituted in equal volumes of 100% formic acid (Sigma-Aldrich) and acetonitrile (Sigma-Aldrich) (in 20 μl volumes), mixed all right. A microliter of supernatant was placed in a 96-point steel plate (Bruker Daltonik) and allowed to dry at room temperature before the addition of 1 μl of the α-cyano-4-hydroxycinnamic acid matrix. Each sample was tested in duplicate. A score was obtained according to the manufacturer\'s technical specifications as follows: correct genus and species identification (≥2.0), secure genus identification (1.7--2.0), and no reliable identification (\<1.7).

Multilocus sequence typing {#sec2-2}
--------------------------

*C. albicans* isolates were typed using MLST with the internal regions of seven housekeeping genes (AAT1a, ACC1, ADP1, MPIb, SYA1, VPS13, and ZWF1b) as described previously.\[[@ref10][@ref11]\] Sequencing was performed on both strands using an ABI Prism 3130 xl genetic analyzer (Applied Biosystems, Foster City, CA, USA). All data were entered into the MLST online database (<http://calbicans.mlst.net>). For the analysis, we used the algorithm eBURST which divides an MLST data set of any size into groups of related isolates and clonal complexes, predicts the founding (ancestral) genotype of each clonal complex, and computes the bootstrap support for the assignment.\[[@ref12]\]

Antifungal susceptibility testing {#sec2-3}
---------------------------------

Antifungal susceptibility testing was carried out using the (CLSI-BMD), following the M27-A3 guidelines\[[@ref13]\] for triazoles (fluconazole (FLU), itraconazole (ITZ), voriconazole (VRZ), posaconazole (POS), and isavuconazole (ISA)), caspofungin (CAS), and amphotericin B (AMB). The minimum inhibitory concentrations (MICs) were visually determined as the lowest concentration of drug that caused a significant diminution (MIC -- 0 or 0% amphotericin B/MIC -- 2 or ≥50% others) compared with that of the drug-free growth control after 24 h of incubation for caspofungin and amphotericin B, and after 48 h for triazoles. Quality control was ensured by testing the CLSI-recommended strains *Candida* parapsilosis ATCC 22019 and *Candida* krusei ATCC 6258.\[[@ref14]\]

Invertebrate *Galleria mellonella* model {#sec2-4}
----------------------------------------

Killing assays were performed in *Galleria mellonella* as described by Fallon, 2012.\[[@ref15]\] Briefly, larvae of late stages (fifth and sixth) between 250 and 330 mg and a length of approximately 2 cm were selected. A group of ten larvae was used for each of the controls: absolute control, disinfection, and inoculation. To compare mortality, three biological replicates were performed with ten larvae for each isolate evaluated. The strain *C. albicans* SC5314 was used as a control of pathogenicity. The isolates were grown in Sabouraud dextrose agar and incubated for 48 h at 27°C. Suspensions, adjusted to 3.10^5^ UFC/ml using Neubauer chamber, were used to inoculate ten larvae per isolate, each with 10 μl of inoculum by injection into the last left proto-leg using a 0.5 ml gauge insulin syringe. After inoculation, larvae were placed in Petri dishes and incubated in darkness at 37°C, and the number of dead larvae was recorded daily.\[[@ref10]\] Survival analysis was performed using the Kaplan--Meier method in Graph Pad Prism version 5.0, Software Inc., La Jolla, CA, USA..

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Culture and identification {#sec2-5}
--------------------------

The retrospective study allows us to recover 16 *C. albicans* isolates from different anatomical sites including oral cavity (*n* = 4), respiratory secretions (*n* = 3), stool (*n* = 5), palate (*n* = 1), and urine (*n* = 3). A *Candida* guilliermondii was also isolated from the oral cavity in 2017.

Multilocus sequence typing {#sec2-6}
--------------------------

The analysis identified the same diploid sequence type (DST) in all the 16 isolates of *C. albicans* recovered from the patient, which was the 62/3/3/3/3/39/95 allele profile that corresponds to the DST918 and clade 9. This indicates that these successive infectious episodes by *C. albicans* correspond to recurrences by the same DST and are not reinfections by different types of DSTs. Moreover, we employed 84 DSTs representative of clade 9 to which the previously identified DST 918 belongs. These DSTs, retrieved from the database, originated from different sources, including blood, oropharynx, oral cavity, and animals from France, USA, Australia, Guyana, Ireland, Kuwait, Israel, and Brazil reported in different years (2000, 2001, 2002, 2007, 2008, 2010, and 2013). To perform this analysis, we took a representative cluster of clade isolate 9 which evidence the cluster clone 1 based on founding genotype in blue circle (DST 735) as the putative founding type, subgroup founder yellow circle DST 918 to which the identified genotype belongs in the patient and 5 singleton DSTs are illustrated in [Figure 1b](#F1){ref-type="fig"}.

Antifungal susceptibility testing {#sec2-7}
---------------------------------

Through determination of the resistance profiles of the 16 *C. albicans* and C. guilliermondii isolates \[[Figure 2b](#F2){ref-type="fig"}\], we observed that the initial isolate 0218 PUJ/HUSI (Isolate 1) was susceptible to all antifungal tested, whereas the other isolates were susceptible to CAS and AMB but resistant or nonwild type to azoles. We found a minimal decrease in the MIC to itraconazole after it was stopped \[[Figure 2](#F2){ref-type="fig"}\]. In contrast, the C. guilliermondii isolate exhibited susceptibility to all azoles tested.

Invertebrate *Galleria mellonella* model {#sec2-8}
----------------------------------------

We compared the pathogenicity of 16 *C. albicans* isolates in a systemic infection model using the insect larval *G. mellonella* model. The concentration of 3.10^5^ UFC/ml per larva did not exhibit significant differences in the 10 days of tracking (*P* = 0.2483) \[[Figure 3](#F3){ref-type="fig"} and Supplement Figure 1\].

![Survival curve of average according to anatomical origin. Kaplan--Meier plots of *Galleria mellonella* survival after infection with *Candida albicans* 3.10^5^ UFC/ml. inside the brackets the number of samples](JGID-12-16-g003){#F3}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

A complete phenotypic and genotypic characterization of *C. albicans* isolates associated to a complicated case of CMC was conducted in the 2012--2016 period. Samples collected over this a period of 4 years, allow us to identify the same DST918 which belongs to clade 9, being this DST widely reported worldwide. It is important to highlight that among the 22 isolates reported to date with the same DST, none had been previously associated with CMC (<https://pubmlst.org/calbicans/>).\[[@ref16][@ref17]\] *C. albicans* quickly adapts to new microenvironments, and our analysis shows that a clonal population with the same DST was stable over time and was present in all the sampled anatomic sites, whereas, the first three sequential isolates exhibited very different resistance profiles, no difference in pathogenicity or fitness was demonstrated in the invertebrate model *G. mellonella*. Interestingly, this clone was maintained through large periods, yet it did not disappear or was not replaced regardless of all the administered antifungals.

The Th17 cells are the most important source of IL 17, an important cytokine for defense against *Candida* that induce antimicrobial peptides production. The perturbation of this aspect can lead to overgrowths of *Candida* which may be damaging to the host.\[[@ref3][@ref18][@ref19]\] Herein, we corroborate it with a patient who has a mutation in STAT1. It is well known that STAT1 is involved in tumor genesis and tumor suppression with reports of reduced levels in transformed cancer cells and poorer outcomes if it is absent. Patients with CMC have an increased risk of both oral and esophageal cancers, the majority developing squamous cell carcinomas of skin, larynx, and gastrointestinal tract.\[[@ref2]\] To date, the patient from this study does not present anything related to cancer.

We believe that immunosuppression in the patient plays an important role in the maintenance of a clonal population in the tissue throughout the years, and granulomatous lesions classically described in the CMC clinical entity could explain the yeast persistence.\[[@ref20]\] Some studies have reported successful outcomes of azole refractory CMC after treatment by amphotericin B or echinocandins. We highlight these results as the first evidence in Colombia and South America *Candida* isolates resistant to antifungal therapy remains a concern.\[[@ref21]\] In the Toubiana series, resistance to at least one antifungal was observed in 39% of patients treated with long-term antifungal therapy and in 15% of patients treated intermittently, with azole resistance being the most common.\[[@ref8]\]

The robust characterization of isolates was pivotal for understanding the outcome of our patient. The stability and persistence of *C. albicans* has been highlighted previously in MLST studies using isolates taken at serial time points in a range of clinical settings.\[[@ref22]\] However, the MLST methodology has some limitations such as the fact that only seven regions of constitutive genes varying between 350 and 490 bp were analyzed. This can explain why isolates with identical DSTs may differ significantly between them, through large genomic rearrangements in other regions that are not included in the analyzed loci.\[[@ref23]\] Hence, further follow-up and characterization of the isolates are needed to reach accurate conclusions. In addition, since the analyzed gene sequences are not related to genes implicated in antifungal resistance or pathogenicity, we must continue the search of new molecular markers, which allow associating the phenotypic and molecular characteristics with the clinical presentation of the disease.

Whereas, the first three sequential isolates exhibited very different resistance profiles; no difference in pathogenicity or fitness was demonstrated in the invertebrate model *G. mellonella*.
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